BioMarin Pharmaceutical (BMRN)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$55.95-1.20%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge BioMarin Pharmaceutical’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-3.3%

+10% or more+5%0%−5%−10% or less

6.64 → 6.43 EPS · FY ending Dec 31, 2027 · 13 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 16 to 13; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	1.14B
EPS	—	1.683
FY 2026 · Annual
Revenue	At least $1B	3.92B
EPS	—	3.535
FY 2027 · Annual
Revenue	—	4.49B
EPS	—	6.426

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain competitive edge in rare disease treatments	BioMarin grows revenue about 24% a year, helped by new rare disease treatments.	Improving	Competitors erode market share significantly	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income improves to positive territory	A primary condition in BioMarin Pharmaceutical's published investment case. The stated target is Operating income > $100M.	Intact	Operating income falls below breakeven next year	Operating income: $110.92M FY2026-Q2; GAAP. Published target: Operating income > $100M. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026110,920,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 9c237695-a94a-4a83-8141-177c5aeb628f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
BioMarin's total revenue grows to about $3.9 billion	BioMarin grows revenue about 24% a year, helped by new rare disease treatments.	Intact	Revenue falls below $3.2B in FY26	Revenue: $989.708M FY2026-Q2; GAAP. Published target: ~$3.9B. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026989,708,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 9c237695-a94a-4a83-8141-177c5aeb628f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. VOXZOGO revenue increased from $220M in 2026-Q1 to $253M in 2026-Q2, with full-year 2026 guidance raised to at least $1 billion. VOXZOGO grew 26% year-over-year in 2025. Enzyme Therapies revenue grew 6% year-over-year in 2026-Q1. Management is delivering consistent revenue growth in these key products. Delivery assessment Oct 24, 2026
Complete and integrate Amicus acquisition	A supporting condition in BioMarin Pharmaceutical's published investment case. The stated target is Amicus fully integrated by end 2026.	Improving	Acquisition fails or integration disrupts growth	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$6.43

$6.39 → $6.43 · observed estimates

FY2027 revenue$4.49B

$4.43B → $4.49B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$6.39	$4,427,389,840	16 / 22
2026-07-25	$6.39	$4,427,389,840	16 / 22
2026-07-26	$6.39	$4,427,389,840	16 / 22
2026-07-27	$6.39	$4,427,389,840	16 / 22
2026-07-28	$6.39	$4,427,389,840	16 / 22
2026-07-29	$6.39	$4,427,389,840	16 / 22
2026-07-30	$6.39	$4,427,389,840	16 / 22
2026-07-31	$6.39	$4,427,389,840	16 / 22
2026-08-01	$6.63	$4,442,389,838	15 / 17
2026-08-02	$6.63	$4,442,389,838	15 / 17
2026-08-03	$6.39	$4,427,389,840	16 / 22
2026-08-04	$6.39	$4,427,389,840	16 / 22
2026-08-05	$6.39	$4,427,389,840	16 / 22
2026-08-06	$6.39	$4,427,389,840	16 / 22
2026-08-07	$6.63	$4,442,389,838	15 / 17
2026-08-08	$6.63	$4,442,389,838	15 / 17
2026-08-09	$6.37	$4,443,084,200	16 / 22
2026-08-10	$6.37	$4,443,084,200	16 / 22
2026-08-11	$6.56	$4,450,122,940	16 / 22
2026-08-12	$6.63	$4,455,620,690	17 / 23
2026-08-13	$6.63	$4,455,620,690	17 / 23
2026-08-14	$6.63	$4,442,389,838	15 / 17
2026-08-15	$6.63	$4,442,389,838	15 / 18
2026-08-16	$6.63	$4,442,389,838	15 / 18
2026-08-17	$6.63	$4,442,389,838	15 / 18
2026-08-18	$6.63	$4,442,389,838	15 / 18
2026-08-19	$6.63	$4,442,389,838	15 / 18
2026-08-20	$6.65	$4,454,699,276	15 / 18
2026-08-21	$6.62	$4,454,593,668	16 / 19
2026-08-22	$6.62	$4,454,593,668	16 / 19
2026-08-23	$6.62	$4,454,593,668	16 / 19
2026-08-24	$6.62	$4,454,593,668	16 / 19
2026-08-25	$6.62	$4,454,593,668	16 / 19
2026-08-26	$6.62	$4,454,593,668	16 / 19
2026-08-27	$6.62	$4,454,593,668	16 / 19
2026-08-28	$6.62	$4,454,593,668	16 / 19
2026-08-29	$6.62	$4,454,593,668	16 / 19
2026-08-30	$6.62	$4,454,593,668	16 / 19
2026-08-31	$6.62	$4,454,593,668	16 / 19
2026-09-01	$6.62	$4,454,593,668	16 / 19
2026-09-02	$6.65	$4,474,803,122	16 / 19
2026-09-03	$6.66	$4,474,815,347	16 / 19
2026-09-04	$6.66	$4,474,826,930	16 / 19
2026-09-05	$6.66	$4,474,826,930	16 / 19
2026-09-06	$6.66	$4,474,826,930	16 / 19
2026-09-07	$6.66	$4,474,826,930	16 / 19
2026-09-08	$6.66	$4,474,826,930	16 / 19
2026-09-09	$6.66	$4,474,826,930	16 / 19
2026-09-10	$6.66	$4,474,826,930	16 / 19
2026-09-11	$6.66	$4,475,398,680	16 / 19
2026-09-12	$6.66	$4,474,857,013	16 / 19
2026-09-13	$6.66	$4,474,857,013	16 / 19
2026-09-14	$6.66	$4,474,857,013	16 / 19
2026-09-15	$6.66	$4,474,857,013	16 / 19
2026-09-16	$6.66	$4,474,857,013	16 / 19
2026-09-17	$6.66	$4,473,979,539	16 / 19
2026-09-18	$6.66	$4,473,979,539	16 / 19
2026-09-19	$6.64	$4,477,677,288	16 / 19
2026-09-20	$6.64	$4,477,677,288	16 / 19
2026-09-21	$6.64	$4,477,677,288	16 / 19
2026-09-22	$6.64	$4,477,677,288	16 / 19
2026-09-23	$6.64	$4,477,677,288	16 / 19
2026-09-24	$6.64	$4,477,677,288	16 / 19
2026-09-25	$6.64	$4,477,677,288	16 / 19
2026-09-26	$6.64	$4,477,677,288	16 / 19
2026-09-27	$6.64	$4,477,677,288	16 / 19
2026-09-28	$6.64	$4,477,677,288	16 / 19
2026-09-29	$6.64	$4,477,677,288	16 / 19
2026-09-30	$6.64	$4,477,677,288	16 / 19
2026-10-01	$6.64	$4,477,677,288	16 / 19
2026-10-02	$6.64	$4,477,677,288	16 / 19
2026-10-03	$6.66	$4,477,676,154	16 / 19
2026-10-04	$6.66	$4,477,676,154	16 / 19
2026-10-05	$6.66	$4,477,676,154	16 / 19
2026-10-06	$6.66	$4,477,676,154	16 / 19
2026-10-07	$6.66	$4,477,676,154	16 / 19
2026-10-08	$6.67	$4,477,676,154	16 / 19
2026-10-09	$6.67	$4,480,630,321	16 / 19
2026-10-10	$6.68	$4,481,971,387	16 / 19
2026-10-11	$6.68	$4,481,971,387	16 / 19
2026-10-12	$6.68	$4,481,971,387	16 / 19
2026-10-13	$6.68	$4,481,971,387	16 / 19
2026-10-14	$6.55	$4,475,412,141	16 / 19
2026-10-15	$6.55	$4,475,412,141	16 / 19
2026-10-16	$6.55	$4,484,651,994	16 / 20
2026-10-17	$6.55	$4,484,651,994	16 / 20
2026-10-18	$6.54	$4,485,664,882	17 / 19
2026-10-19	$6.54	$4,485,664,882	17 / 19
2026-10-20	$6.52	$4,485,664,882	17 / 19
2026-10-21	$6.42	$4,487,024,882	17 / 19
2026-10-22	$6.43	$4,487,184,882	17 / 19
2026-10-23	$6.43	$4,488,424,882	13 / 15
2026-10-24	$6.43	$4,488,424,882	13 / 15

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	21	6
2026-06-01	20	6
2026-07-01	20	6
2026-08-01	20	7
2026-09-01	20	7
2026-10-01	22	7

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 22 Buy / Strong Buy · 7 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Morgan StanleyOct 21 · prior Aug 7

$124.00 → $122.00-1.6%

BarclaysOct 14 · prior Aug 17

$111.00 → $114.00+2.7%

$0$68.20$136.40

1 raises · 1 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain competitive edge in rare disease treatmentsQualitative condition
Operating income improves to positive territoryOperating income: $110.92M
BioMarin's total revenue grows to about $3.9 billionRevenue: $989.708M
Complete and integrate Amicus acquisitionQualitative condition

Next proof point

Oct 26, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.2%Typical daily move · historical

Downside history

-22.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

BioMarin Pharmaceutical outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-oriented biotechnology business with recent financial performance rated strong and a healthcare sector backdrop rated favorable. The long-term thesis is intact, while management execution is rated volatile and the evidence snapshot has medium confidence.

What's priced into BioMarin Pharmaceutical

Valuation is about 1.2 times the peer level, while the expectations gap is negative and the valuation signal is described as aligned. The evidence therefore suggests expectations are not unusually fragile, but it does not establish that the shares are cheap; the priced-in tag is justified.

What the fundamentals likely do

Near term, revenue growth has been strong: second-quarter revenue reached $990 million, supported by the Amicus products, and VOXZOGO guidance was raised to at least $1 billion for 2026. Acquisition costs reduced GAAP net income, and debt rose to support the acquisition, though management is targeting lower leverage by mid-2027. The next results carry some execution risk, with a 40% miss probability in the snapshot and guidance cuts flagged as a key negative scenario.

What BioMarin Pharmaceutical hinges on

Over the next one to three years, the thesis depends on integrating Amicus and sustaining growth in GALAFOLD, POMBILITI + OPFOLDA, VOXZOGO, and enzyme therapies while improving profitability and managing debt. A guidance cut or weaker economic data would challenge the near-term setup, while continued strong results from healthcare peers could support sector momentum.